Improving adherence to inhaled iloprost for pulmonary arterial hypertension
AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?
This project will test whether pharmacist-led inhaler training and adherence support helps adults with pulmonary arterial hypertension who use inhaled iloprost stick to their treatment and reduce side effects.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 72 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Sao Paulo General Hospital Academic / other |
| Locations | 1 site (São Paulo, São Paulo) |
| Trial ID | NCT07457762 on ClinicalTrials.gov |
What this trial studies
Adults with invasively confirmed PAH who are using inhaled iloprost at a referral center will receive pharmacist-delivered guidance on inhaler technique and medication adherence. The intervention includes hands-on training, counseling about side-effect management, and periodic follow-up to reinforce correct use and dosing frequency. Study outcomes will include measures of medication adherence, inhalation technique, adverse events, and functional status. The goal is to see if pharmacist support can improve real-world use and tolerability of inhaled iloprost in PAH patients.
Who should consider this trial
Good fit: Adults (≥18) with invasively confirmed PAH who are being treated with inhaled iloprost at the Heart Institute of the University of São Paulo and who can perform the 6-minute walk test are ideal candidates.
Not a fit: Patients not using inhaled iloprost, those treated outside the referral center, or those unable to perform the 6-minute walk test are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, patients could have better adherence to inhaled iloprost, fewer inhalation-related problems, and potentially improved functional outcomes.
How similar studies have performed: Pharmacist-led inhaler training has improved adherence and technique in asthma and COPD, but this specific approach is novel and under-studied in PAH.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * "Adult patients aged ≥ 18 years, treated at the referral center for PH management at the Heart Institute of the University of São Paulo Medical School, with an invasive confirmed diagnosis of PAH (mean pulmonary arterial pressure \[mPAP\] greater than 20 mmHg at rest, pulmonary vascular resistance \[PVR\] equal to or greater than 2 Wood units, and pulmonary capillary wedge pressure \[PCWP\] equal to or less than 15 mmHg), and who have been using Iloprost. Exclusion Criteria: * Patients who are unable to perform the 6-minute walk test (6MWT) or who have experienced gastrointestinal bleeding within the 12 weeks prior to the start of the study will be excluded.
Where this trial is running
São Paulo, São Paulo
- Incor HCFMUSP — São Paulo, São Paulo, Brazil (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.